Virus Diagnostics and Antiviral Therapy in Acute Retinal Necrosis (ARN)

Peter Rautenberg¹, Jost Hillenkamp², Livia Grančičova¹, Bernhard Nölle², Johann Roider² and Helmut Fickenscher¹*

¹Institute for Infection Medicine,
²Department for Ophthalmology, Christian Albrecht University of Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany

1. Introduction

Acute retinal necrosis (ARN) is a fulminant necrotizing form of retinitis of viral origin. Without treatment, ARN leads to the irreversible blindness by destruction of the retina and the optic nerve. The clinical observation was first described under the term Kirisawa uveitis (Urayama et al., 1971) while the term acute retinal necrosis was introduced by Young & Bird (1978). The international diagnostic standard criteria were defined by Holland et al. (1994). ARN is a rare disease occurring world-wide in approximately one per 1.5-2.0 million persons per year (Muthiah et al., 2007; Vandercam et al., 2008). The rareness of this disease precludes randomized prospective clinical studies. Most observations are derived from small case series and homogenous international guidelines for therapy are still lacking. A few studies, however, allow statements on the causative agents and therapeutic principles.

Initially, herpesvirus particles were detected by electron microscopy in the retina of enucleated eyes with ARN. The causative role of herpesviruses was further established by showing local virus-specific antibody production, by demonstrating viral nucleic acids with the polymerase chain reaction (PCR), and by therapeutic success with antiviral drugs (Culbertson & Atherton, 1993). The disease is mainly caused by the α-herpesviruses varicella-zoster virus (VZV) or herpes-simplex virus (HSV) in 70% and 30% of the cases, respectively (e.g., Culbertson et al., 1986; Rummelt et al., 1992). While the β-herpesvirus cytomegalovirus (CMV) plays a marginal role in the pathogenesis of ARN, the role of the γ-herpesvirus Epstein-Barr virus (EBV) remains controversial. Meta-analysis shows that men are affected slightly more frequently than women (Rautenberg et al., 2009).

The early ARN diagnosis is primarily based on the virus-specific polymerase-chain reaction in punctuate fluid from the anterior chamber or the vitreous and can be supported by the detection of specific antibody titers from punctate fluid and serum using the Goldmann-Witmer coefficient. Detection of virus DNA provides the basis for the early antiviral therapy which limits disease progression and risk for complications. Retinal infections by VZV or HSV are treated with aciclovir, valaciclovir, or famciclovir. Ganciclovir and valganciclovir are primarily used for the therapy of retinal CMV infections. In the case of resistance
development against antiviral drugs, foscarnet or cidofovir are available as second-line antiviral drugs. The early specific antiviral therapy is the crucial prerequisite for the optimal clinical outcome. The pros and cons of the different application routes (oral, intravenous, intravitreal) are discussed in order to provide sufficient drug levels in the eye. The antiviral therapy of ARN must be combined with ophthalmological and surgical procedures. Early vitrectomy has been shown to lead to a significant reduction of secondary retinal detachment. The early and combined strategy is essential for the clinical outcome of the rare ARN (Hillenkamp et al., 2009a, b, 2010; Pleyer et al., 2009).

2. Pathogenesis, epidemiology, and clinical course of ARN

2.1 Viral pathogenesis

The establishment of latency after primary infection is a common feature of herpesviruses. During latency, the entire, mostly inactive virus genome is maintained in the nuclei of host cells. The α-herpesviruses VZV, HSV-1, and HSV-2 are characterized by their tropism for sensory neurones and epithelia. Via mucosal or cutaneous entry sites, the neurotropic herpesviruses gain access to the peripheral endings of sensory neurones. After virus uptake and axonal transport of the nucleocapsids, the virus establishes latency within approximately 14 days in the nucleus of autonomous or sensory ganglia. The viral genome persists there in circular, extrachromosomal form (Steiner et al., 2007).

In case of HSV, production of latency-associated viral transcripts seems to block virus replication and neuronal cell death. HSV-1 was shown to induce a local, CD8+ T cell-mediated, non-lytical inflammation in human trigeminal ganglia (Mott et al., 2009; Theil et al., 2003). These CD8+ T cells seem to block HSV reactivation via release of granzyme B which selectively degrades one of the regulatory proteins of HSV-1 and inhibits reactivation already in the very early phase (Khanna et al., 2004; Knickelbein et al., 2008). Thus, a well balanced equilibrium between host defense and viral immune evasion mechanisms is formed during herpesviral latency. Since virus particles are not produced during latency, virus elimination by antiviral drugs is not feasible.

The factors are not well defined which induce the reactivation of herpesvirus replication and the axonal transport of the viral nucleocapsids from the ganglion to the periphery. For HSV, ultraviolet light, neurosurgical procedures, periorcular trauma and high-dosed steroid medication are known to cause reactivation. During peripheral virus replication, clinical symptoms are observed in the region innervated by the respective sensory nerve, mostly in the form of orofacial herpes or as herpes zoster (shingles) and by far more rarely as ocular herpes (Liesegang, 2001; Lorette et al., 2006; Malvy et al., 2007).

The extremely low incidence of the ocular herpes manifestations can be explained through epidemiology as well as neuroanatomy. HSV-1 and HSV-2 have strongly different capabilities of establishing latency in trigeminal or sacral sensory ganglia and of inducing reactivation. Whereas 41% of the cases with latent trigeminal HSV-1 reactivate the virus, this occurs only in 4% of the trigeminal HSV-2 infections. In latent sacral HSV-2 infections, 89% of the patients develop recurrent genital herpes, in contrast to 25% of the cases with sacral HSV-1 latency (Lafferty et al., 1987). The rate for the symptomatic recurrence of orofacial HSV-1 is 0.12 per month in contrast to 0.001 for orofacial HSV-2 (Lafferty et al., 1987). The different rates of reactivation from different anatomical regions correspond to the mRNA prevalence...
as detected by PCR in trigeminal ganglia, 79% for VZV, 53% for HSV-1, and 7% for HSV-2, respectively (Pevenstein et al., 1999). Moreover, the HSV-specific latency-associated transcripts and HSV-reactive CD8+ T cells were clearly less frequent in the neurones projecting to the ophthalmic nerve as in the other branches of the trigeminal nerve (Hüfner et al., 2009). These findings indicate that HSV reactivations occur more rarely in the eye than in the other orofacial regions.

As the latency site of CMV, hematopoetic myelomonocytic progenitor cells are considered, from which systemic dissemination occurs via monocytes (Crough et al., 2009; Sinclair, 2008; Sinclair & Sissons, 2006). EBV replicates primarily in the pharyngeal and tonsillar epithelium and in B cells. EBV latency is localized to quiescent B lymphocytes (Miyashita et al., 1995). Both viruses can be reactivated spontaneously or, drastically more frequently, during immunosuppression. Correspondingly, the simultaneous demonstration of DNA of different herpesviruses is possible in retinitis or ARN (Hasselbach et al., 2008; Hillenkamp et al., 2009a; Lau et al., 2007; Sugita et al., 2008).

The mechanisms are not yet sufficiently clarified which lead to the viral infection of the retina and finally to ARN. In a murine model, retinitis of the contralateral eye was observed within three days after intravitreal inoculation with a highly neurovirulent HSV-1 strain (Labetoulle et al., 2000). The time course of virus spread and immunohistological findings support the theory of non-synaptic virus transfer between neurones and glia cells in the chiasma opticum leading to the infection of the contralateral eye (Labetoulle et al., 2000). This is clinically relevant, since specific antiviral therapy reduces the risk for bilateral ARN (Palay et al., 1991).

For rare diseases such as herpesviral encephalitis or ARN, causative immunological defects have been discussed. In one study, plasmacytoid dendritic cells from nine ARN patients were significantly fewer than in healthy controls, as well as interferon-α production and CD8+ cell responses were clearly diminished. This could contribute to the impaired control of latent herpesvirus infections and subsequent development of ARN (Kittan et al., 2007).

2.2 Epidemiology

ARN is an extremely rare disease. Patients with endogenous uveitis had ARN in 1.3% (41 of 3060; 95% confidence interval [CI]: 0.97-1.83%; Goto et al., 2007). During a prospective study in Great Britain over a period of 12 months, an ARN incidence of 0.5-0.6 per million was determined (Muthiah et al., 2007). Retrospective results were obtained for the Netherlands with a similar incidence of 1.1-1.6 per million (Vandercam et al., 2008). Approximately 55% of ARN patients are men (Fig. 1; Rautenberg et al., 2009: ratio men/women: 1.18; 95% CI: 1.06-1.29). In contrast, only 37.7% of the patients with orofacial herpes are men (95% CI: 33-43%; Lorette et al., 2006), while HSV seroprevalence is identical in both genders (Malkin et al., 2002).

More than 97% (95% CI: 96-99%) of all ARN cases are caused by the α-herpesviruses VZV, HSV-1, and HSV-2. VZV is the most common causative agent of ARN in approximately 70% (Fig. 2; Rautenberg et al., 2009; 95% CI: 66-76%) of ARN cases, followed by HSV-2 and HSV-1. The age of ARN manifestation depends on the causative agent. Patients with VZV-induced ARN were 48.8±19.6 years old (mean ±1 standard deviation; Fig. 3). The mean age of HSV-1- or HSV-2-induced ARN patients was 31.1±17.5 or was 47.8+-19.2 or 31.1+-17.5 years, respectively.
Fig. 1. Gender distribution in ARN patients. The total value (diamond) indicates slightly more men than women (54% men vs. 46% women).

Fig. 2. Fraction of patients with VZV-induced ARN. The total value (diamond) indicates a favourite role of VZV (about 70%) in this rare disease.
(Ganatra et al., 2000; Itoh et al., 2000; Kychenthal et al., 2001; Rahhal et al., 1996; Schlingemann et al., 1996; Tran et al., 2003b; van Gelder et al., 2001). According to these results, a cut-off value of 36 years allows to discriminate HSV-2 from the other herpesvirus-induced ARN (Fig. 3; sensitivity: 64%; specificity: 83%; positive predictive value at 30% prevalence: 56%; negative predictive value at 30% prevalence: 84%). The diagnostic discrimination between ARN caused by HSV-1, HSV-2, or VZV is not highly relevant, since the therapy is identical in these cases, primarily by aciclovir.

In contrast, the virological and clinical discrimination of CMV retinitis from ARN caused by the three α-herpesviruses is very important, since the drug of choice is ganciclovir in CMV infections. CMV as the causative agent of a viral retinitis in absence of immunosuppressive therapy in immunocompetent patients is extremely rare. To our knowledge, only four such cases were documented in the literature (Silverstein et al., 1997; Tajunisah et al., 2009; Urayama et al., 1971; Voros et al., 2006).

Fig. 3. Age-distribution of patients who contracted ARN by different herpesviruses. Analysis showed a significant younger age in patients who were infected by HSV-2 as compared to the other herpesviruses. The triangle within the box indicates the mean.

The controversial role of EBV for ARN was investigated in a case control study (Ongkosuwito et al., 1998). By qualitative PCR, EBV was detected in one out of 24 ocular ARN samples. However, three of 46 vitreous samples from a control group also contained EBV DNA (odds ratio: 0.62; 95% CI: 0.06-6.34). Therefore, an association between the demonstration of EBV DNA and ARN could not be determined. Only a few studies analysed EBV DNA prevalence in ARN (Abe et al., 1996; Hillenkamp et al., 2009a; Itoh et al., 2000; Lau et al., 2007; Ongkosuwito et al., 1998; Sugita et al., 2008; Tran et al., 2003a; Yamamoto et al., 2008). In nine of 134 ARN patients, EBV DNA was detected from ocular samples. In seven of these nine ARN patients (78%; 95% CI: 40-96%) VZV DNA was detected in addition to EBV by PCR (Hillenkamp et al., 2009a; Lau et al., 2007; Sugita et al., 2008). In theory, quantitative PCR methods could contribute to a clarification. However, there are no standard values for clinically relevant DNA concentrations in ocular materials and neither the diagnostic
samples nor the PCR methods are sufficiently standardized. In summary, EBV seems to play
no or -if at all- only a minor role in ARN development.

2.3 Clinical course
Almost 90% of all ARN cases remain unilateral (Hillenkamp et al., 2009a; Muthiah et al.,
2007; Usui et al., 2008; Vandercam et al., 2008). In approximately 10% of the patients, also the
centralalateral eye is affected within one to six weeks, in an extreme case after up to 34 years
(Falcone & Brockhurst, 1993; Saari et al., 1982; Schlingemann et al., 1996). A case-control
study revealed that aciclovir therapy considerably reduces the risk for the centralalateral eye
(Palay et al., 1991). As soon as the ARN diagnosis is made, antiviral therapy should be
started in order to avoid disease progression. Longer termed aciclovir prophylaxis should be
considered (Cordero-Coma et al., 2007).

An increased ARN risk was discovered for the HLA alleles DQw7, DR4, and Bw62 (odds
ratio: 5.2 and 7.3 respectively; Holland et al., 1989). Moreover, there is a 20-fold increased
risk (p=0.05) for a fulminant ARN course in the presence of the HLA DR9 allele (Matsuo &
Matsuo, 1991). Several case reports describe ARN following HSV encephalitis (Bristow et al.,
de la Blanchardiere et al., 2000; Gain et al., 2002; Ganatra et al., 2000; Gaynor et al.,
2001; Hadden & Berry, 2002; Kim & Yoon, 2002; Maertzdorf et al., 2001; Pavésio et al., 1997;
Yamamoto et al., 2007). In a retrospective study, thirteen of 32 patients showed infectious or
non-infectious neurological diseases in the medical history (Vandercam et al., 2008). Four of
eleven patients had HSV encephalitis 20.6 months (mean) prior to ARN. Two of 28 patients
had VZV encephalitis 28 months (mean) before. The HSV patients showed a unilateral ARN,
whereas both immunosuppressed VZV patients developed bilateral ARN. Besides various
case reports, these results clearly demonstrate herpes encephalitis as a risk factor for ARN
which needs attention in neurology and ophthalmology.

3. Virus diagnostics
3.1 Preanalytical conditions
Diagnostic samples can be generated in early stages by puncture of the anterior chamber, by
paracentesis, by fine needle aspiration of vitreous fluid, or in advanced conditions by therapeu-
tic pars plana vitrectomy (Winterhalter et al., 2007). The rapid PCR demonstration of
virus DNA is highly important for the therapy, because specific antiviral drugs are used.
Since herpesviruses and their DNA genomes are rather stable, the transport of fluid from
the anterior chamber or from the vitreous does not need special precautions. Only in the
case of prolonged transport times, the samples should be shipped in cooled conditions. The
major diagnostic test is the PCR for herpesviral DNA for the direct demonstration of the
causative agent. Virus-specific serologic tests can serve as indirect methods in order to show
local antibody production at delayed time points. The major advantage of PCR testing is the
low sample volume required and the independence of time-delayed immune reaction. Due
to the rareness of ARN and to the critical contribution of antiviral therapy, the authors re-
commend the genotypic sensitivity test after demonstration of herpesvirus DNA. In case of
failure of the antiviral therapy, this allows the rapid decision for either switching to cidofo-
vir or foscarnet or for increasing aciclovir dosage in case of preserved drug sensitivity.
3.2 Nucleic acid diagnostics

The clinical ARN diagnosis needs the critical validation by virus-specific PCR. During the initial stage, only PCR allows rapid and valid results. Time-delayed PCR diagnostics lead to diminished test sensitivity (de Boer et al., 1996; Knox et al., 1998). Due to the high test sensitivity of the PCR, 20-50 μl sample volume is sufficient in most cases. The PCR discrimination between HSV-1 and HSV-2 is an established method. Real-time PCR methods allow the quantitation of viral loads in copy number per ml. Although there are no standards available for a clinically relevant virus load value, the quantitation is relevant to discriminate between the major causative agent and an additional, perhaps weak reactivation of another herpesvirus, e.g., under immunosuppression (Hasselbach et al., 2008).

3.3 Antibody assays

The quantitative determination of antibody titers from the anterior chamber or the vitreous in comparison to the serum levels is an indirect and supporting procedure for virus-specific diagnostics at delayed time points. For the determination of the Goldmann-Witmer coefficient (antibody index, AI; Goldmann & Witmer, 1954), the intraocular and serum antibody titers and total IgG values are included in the following formula:

$$AI = \frac{\text{antibody titer punctate/antibody titer serum}}{\text{total IgG punctate/total IgG serum}}$$

Most authors consider an AI > 2-3 an obvious indicator of intraocular antibody production (de Boer et al., 1994; Dussaix et al., 1987; Fekkar et al., 2008; Pepose et al., 1992). Serological procedures have the disadvantages that significant antibody levels can be expected only after one to two weeks and that a false-negative AI can result from massive disturbance of the blood-eye barrier. In the case of latently persisting herpesviruses, an ocular reactivation does not necessarily lead to a significant AI increase. Moreover, there are serological cross-reactivities between HSV and VZV (Pepose et al., 1992). Finally, the intraocular antibody generation can be variable in immunosuppressed or HIV-infected patients (de Boer et al., 1996; Doornenbal et al., 1996; Kijlstra et al., 1989, 1990).

4. Therapy

4.1 Drugs directed against α-herpesviruses

Aciclovir by the parenteral route is the drug of choice in severe, acute HSV or VZV infections. The acyclic guanosine derivate aciclovir is specifically activated by the viral enzyme thymidine kinase of HSV or VZV to its monophosphate. Ubiquitous cellular kinases are responsible for the conversion to aciclovir triphosphate which is a specific inhibitor for the viral DNA polymerase (de Clercq, 2004). The dosage is based on tissue culture-derived determinations of the 50%-inhibitory concentration (IC50) of aciclovir against HSV-1, HSV-2, or VZV. Due to a lack of standardisation of the assay conditions and the test viruses, these values are variable, up to several orders of magnitude. The IC50 values were 0.02 to 13.5 μg/ml for HSV-1, 0.01 to 9.9 μg/ml for HSV-2 and 0.12 to 10.8 μg/ml for VZV (O’Brien & Campoli-Richards, 1989). Due to the three hours half life of aciclovir, it should be administered intravenously at 10 mg/kg for ten to 14 days three times daily. Consecutively, the oral application of five times daily 800 mg for further six weeks is recommended (Blumenkranz et al., 1986; Duker & Blumenkranz, 1991; Morse & Mizoguchi, 1995; Palay et al., 1991).
recommendation is based on a case-control study in which most of the bilateral ARN cases occurred within a period of six weeks and in which 90% of the bilateral ARN cases could have been avoided by aciclovir therapy (Palay et al., 1991). After the start of the antiviral therapy, new lesions should not occur from the second day on. From the fourth or fifth day on, the retinal infiltrates should show a tendency for regression. After one month, a complete remission should be achieved (Blumenkranz et al., 1986). If this is not accomplished, either there was an insufficient drug dosage, or antiviral resistance has developed which is more frequently seen in immunosuppressed patients. The side effects of aciclovir are rather weak and rare and may include mild serum creatinine increase, nausea, and vomiting. Presently, the authors recommend aciclovir as first-line therapy of choice in the early phase of the disease. This is based on the long-termed experience with this drug. Moreover, this excludes influences from the intra- and interindividual variability of the oral bioavailability of valaciclovir (Hillenkamp et al., 2009a, b, 2010; Phan et al., 2003). The management of ARN by antiviral drugs has been summarized in a recent review article (Tam et al., 2010).

Valaciclovir is the valyl ester of aciclovir, which is quickly taken up into enterocytes after oral administration via enteric aminoacid transport systems and which is then hydrolyzed to the active prodrug aciclovir (Granero & Amidon, 2006; Katragadda et al., 2005). The oral bioavailability of valaciclovir of 54% is three times higher than that of aciclovir (Soul-Lawton et al., 1995). When 1000 mg valaciclovir were administered three times daily, aciclovir serum levels of 4.41 μg/ml and aciclovir levels in the vitreous of 1.03 μg/ml were reached. These concentrations are in the IC50 range for most HSV or VZV isolates. The lower peak concentrations during oral in comparison to parenteral aciclovir therapy minimize the risk for renal side effects (Huynh et al., 2008).

Famciclovir is an orally available di-acetyl derivate of penciclovir. By deacetylation, famciclovir is metabolized in the liver to the active prodrug penciclovir which is secreted without modification by the kidneys (Chakrabarty et al., 2004). The oral bioavailability of famciclovir is 77% and, thus, approximately 1.5-fold higher than that of valaciclovir (Soul-Lawton et al., 1995) or 3.4-fold higher than that of aciclovir (15–30%; Fletcher & Bean, 1985). By oral administration of 500 mg every eight hours, intravitreal penciclovir concentrations of 1.2 μg/ml can be reached (Chong et al., 2009), which is appropriate for the therapy of non-resistant HSV-1, HSV-2, or VZV strains. In some single case reports, famciclovir was active against aciclovir-resistant VZV strains (Figueroa et al., 1997). However, the main reasons for aciclovir resistance are mutations of the viral thymidine kinase gene, which would typically also result in penciclovir resistance.

Based on case reports with orally available prodrugs of aciclovir (Emerson et al., 2006; Savant et al., 2004), a pilot study was performed with ten eyes of eight patients (Aizman et al., 2007). Under the oral therapy with 1 g valganciclovir or 500 mg famciclovir three times daily, the ARN regression occurred within six days and the maximal improvement within 17 days without any case of contralateral ARN during further 36 weeks of observation. As long as randomized prospective studies on the efficiency of the oral aciclovir alternatives are not yet available, the initial standard therapy should be performed with intravenous aciclovir, only.

Resistance mutations. Especially in immunosuppressed patients, resistance development against aciclovir is observed frequently. However, underdosage must be excluded first. Under optimal conditions, the genotypic viral resistance can be determined by DNA PCR
and sequencing of the viral gene for thymidine kinase and by the sequence comparison with known resistant viruses within a few days. The cultural resistance testing depends on the successful virus isolation. This procedure is slower, hardly standardized and only possible in a few reference laboratories. More than 90% of the resistance cases result from mutations of the thymidine kinase gene. In case of resistance, cidofovir and foscarnet are usually the only available alternatives, since their activity mechanism is independent of the viral thymidine kinase. Both drugs can also be used for ganciclovir-resistant CMV strains.

Cidofovir is an acyclic nucleosid phosphonate with a broad activity spectrum against DNA viruses (de Clercq & Holý, 2005). Host cell kinases convert cidofovir to the active diphosphonyl ester which acts as a competitive inhibitor of the viral DNA polymerases and induces viral DNA chain termination. Aciclovir-resistant virus strain may be susceptible to cidofovir. The drug is administered intravenously since its oral bioavailability is only 5%. The peculiarity of cidofovir is its very high intracellular half-life time of more than 24 hours (de Clercq & Holý, 2005). Cidofovir should be used only as a drug of second choice. It is infused in a dose of 5 mg/kg over one hour once weekly in two weeks. For maintenance, the infusion is then repeated every second week in the same dosage. The major disadvantage of cidofovir is its nephrotoxicity which is due to the accumulation of this drug by an anion transporter system of the proximal tubuli of the renal cortex (Ho et al., 2000). Since cidofovir is renally secreted, it must be combined with probenecid for kidney protection.

Foscarnet. In the case of a proven resistance against aciclovir, ganciclovir, or their prodrugs, foscarnet is the drug of choice. Foscarnet is a pyrophosphate analogon which occupies the pyrophosphate binding site on the herpesviral DNA polymerase and inhibits the release of pyrophosphate from the terminal nucleotide triphosphate of the growing viral DNA chain (Biron, 2006). Due to the very low oral bioavailability of 20%, the drug is administered by large-volume intravenous infusions. Foscarnet is used in a dosage of 60 mg/kg every eight hours. Foscarnet is renally eliminated without any metabolic modification. In patients with diminished renal function, the dosis must be adjusted to the creatinine clearance value. The major side effect of foscarnet is its nephrotoxicity.

Intravitreal application. Vitreous concentrations of aciclovir following intravenous administration has not yet been tested on a broad basis. Therefore, in patients, who do not respond to intravenous therapy, the intravitreal application of the respective antiviral drug should be considered in order to rapidly achieve high concentrations of the drug and, thus, an improved prognosis (Hillenkamp et al., 2009a, 2010; Scott et al., 2002; Velez et al., 2001; Zambarakji et al., 2002). This strategy allows high intraocular drug levels under reduced systemic exposure. Studies on repeated injections are not yet available.

4.2 Drugs directed against cytomegalovirus

In contrast to the α-herpesviruses, CMV lacks a viral thymidine kinase. Presently, four drugs are licensed for CMV therapy: ganciclovir, valganciclovir, cidofovir, and foscarnet. All of them target the viral DNA polymerase and inhibit the viral DNA synthesis.

Ganciclovir and its orally available valyl ester-derivate valganciclovir are the drugs of first choice for the therapy of CMV-induced diseases (de Clercq, 2004). The substances are monophosphorylated in CMV-infected cells by the CMV-specific protein kinase UL97, and subsequently triphosphorylated by cellular kinases. The incorporation of the acyclic
ganciclovir triphosphate into the growing viral DNA chain results in the blockade of polymerase translocation (Reid et al., 1988). Since the oral bioavailability of ganciclovir is only approximately 5%, the drug should be administered intravenously during the ganciclovir disease. In most cases, 10 mg/kg i.v. daily should be sufficient for the CMV therapy in ARN cases. The oral bioavailability of valganciclovir is approximately 60%. A daily dose of 900 mg will yield serum concentrations comparable to 5 mg/kg intravenous ganciclovir or a 1.7-fold serum concentration in comparison to 1000 mg oral ganciclovir (Cvetković & Wellington, 2005). The major side effect of systemic ganciclovir therapy is neutropenia in approximately 8% of the patients. Therefore, ganciclovir therapy needs the regular control of blood counts, as well as the surveillance of renal function (Paya et al., 2004).

**UL97 resistance mutations.** Mutations of the UL97 protein kinase of CMV are the major cause of resistance against ganciclovir and its derivates. The resistance is determined genotypically by sequencing if the viral genes for the UL97 kinase and for the DNA polymerase. The most frequent ganciclovir resistance mutations in UL97 (codons 460, 520, 590-607) inhibit ganciclovir phosphorylation which is the prerequisite for antiviral activity (Chou et al., 2008). The activity of cidofovir and foscarnet is independent of the protein kinase UL97 and appropriate for the therapy of many DNA viruses.

### 4.3 Differential diagnosis

During the early disease stages, additional infectious agents, rheumatological disorders, autoimmune uveitis, or intraocular lymphomas have to be considered (Table 1). Whereas

<table>
<thead>
<tr>
<th>Disease</th>
<th>Diagnosis</th>
<th>First-line therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARN by varicella zoster virus</td>
<td>PCR</td>
<td>aciclovir</td>
</tr>
<tr>
<td>ARN by herpes simplex virus</td>
<td>PCR</td>
<td>aciclovir</td>
</tr>
<tr>
<td>ARN by cytomegalovirus</td>
<td>PCR</td>
<td>ganciclovir</td>
</tr>
<tr>
<td>ARN by Epstein-Barr virus</td>
<td>PCR</td>
<td>not available</td>
</tr>
<tr>
<td>Progressive outer retina necrosis</td>
<td>PCR, serology</td>
<td>dependent on the agent</td>
</tr>
<tr>
<td>Cytomegalovirus retinitis</td>
<td>PCR, serology</td>
<td>ganciclovir</td>
</tr>
<tr>
<td>Lyme borreliosis</td>
<td>serology, PCR</td>
<td>cephalosporin</td>
</tr>
<tr>
<td>Syphilis</td>
<td>serology</td>
<td>penicillin</td>
</tr>
<tr>
<td>Toxoplasmosis retinitis</td>
<td>serology, PCR</td>
<td>pyrimethamine/sulfonamide</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>culture, PCR</td>
<td>antimycobacterial therapy</td>
</tr>
<tr>
<td>Endogeneous endophthalmitis</td>
<td>culture, PCR</td>
<td>dependent on the agent</td>
</tr>
<tr>
<td>Bacterial eye infection</td>
<td>culture</td>
<td>dependent on the agent</td>
</tr>
<tr>
<td>Fungal eye infection</td>
<td>culture, PCR, Antigen</td>
<td>Candida: Fluconazol, Aspergillus: Voriconazol</td>
</tr>
<tr>
<td>Behçet’s disease</td>
<td>clinic, pathergia test</td>
<td>immunosuppression</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>histology</td>
<td>immunosuppression</td>
</tr>
<tr>
<td>Idiopathic chorioretinitis</td>
<td>exclusion diagnosis</td>
<td>immunosuppression</td>
</tr>
<tr>
<td>Idiopathic retinovasculitis</td>
<td>exclusion diagnosis</td>
<td>immunosuppression</td>
</tr>
<tr>
<td>Intraocular lymphoma</td>
<td>cytology, tumor genetics</td>
<td>radiochemotherapy</td>
</tr>
</tbody>
</table>

Table 1. Differential diagnosis of acute retinal necrosis.
the start of ARN therapy is critical for the outcome the initiation of the therapy for most alternative causes is by far less urgent. Due to the similar clinical appearance, toxoplasmosis chorioretinitis is an important differential diagnosis (Balansard et al., 2005; Hasselbach et al., 2008; Moshfeghi et al., 2004). An ocular manifestation of syphilis can show many different symptoms and can mimic various diseases. In contrast to ARN, CMV retinitis shows weak inflammation signs in the anterior chamber and the vitreous. Patients with CMV retinitis are usually infected with human immunodeficiency virus (HIV) with less than 50 CD4+ T cells/μl. CMV retinitis is resistant to aciclovir therapy. Therefore, the early PCR test for virus DNA is necessary.

Finally, progressive outer retina necrosis (PORN) forms another differential diagnosis, which was mainly described in HIV patients (Forster et al., 1990). Typically, the outer retinal layers are primarily affected multifocally, while the inner retinal layers are less concerned. In contrast to ARN, there is no vasculitis component. The course of PORN disease is extremely rapid, spreading to the deep retinal layers and leading to retinal detachment. Patients with PORN usually show coinfection with HIV and VZV.

5. Conclusion

ARN occurs in up to one per million persons per year. The virus-caused disease remains unilateral in approximately 90% of the cases. Without treatment, ARN shows poor prognosis. The immediate calculated antiviral therapy by aciclovir or its prodrugs is justified, since approximately 70% of the cases are caused by VZV and 30% by HSV. The causative role of EBV remains controversial; often, EBV reactivation occurs concomitantly with VZV reactivation. While EBV reactivation cannot be treated efficiently, aciclovir is appropriate for VZV and HSV reactivations. The very rare case of CMV in ARN is an indication for ganciclovir or its prodrug. The virus-specific DNA PCR test from fluid of the anterior chamber or the vitreous provides the critical indication for the specific therapy. Disease progression and complications rates can be limited by additional immediate conservative and surgical therapy.

6. Acknowledgements

The scientific work underlying this manuscript was supported in part by the Deutsche Forschungsgemeinschaft (Bonn), the Excellence Cluster Inflammation at Interfaces (Kiel), and the Varicella-Zoster Virus Research Foundation (New York).

7. References


Virus Diagnostics and Antiviral Therapy in Acute Retinal Necrosis (ARN)


administration of an hPEPT1 inhibitor. Antimicrobial Agents and Chemotherapy, Vol. 47, No. 7, pp. 2351-2353


me in ocular fluids of patients with uveitis. *British Journal of Ophthalmology, Vol. 92, No. 7, pp. 928-932*


The articles that appear in Antiviral Drugs - Aspects of Clinical Use and Recent Advances cover several topics that reflect the varied mechanisms of viral disease pathogenesis and treatment. Clinical management and new developments in the treatment of virus-related diseases are the two main sections of the book. The first part reviews the treatment of hepatitis C virus infection, the management of virus-related acute retinal necrosis, the use of leflunomide therapy in renal transplant patients, and mathematical modeling of HIV-1 treatment responses. Basic research topics are dealt with in the second half of the book. New developments in the treatment of the influenza virus, the use of animal models for HIV-1 drug development, the use of single chain camelid antibodies against negative strand RNA viruses, countering norovirus infection, and the use of plant extracts to treat herpes simplex virus infection are described. The content of the book is not intended to be comprehensive, but aims to provide the reader with insights into selected aspects of established and new viral therapies.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: